https://doi.org/10.55788/735d5736
The COVID-19 pandemic highly influenced the lives of everyone, and in particular of patients with chronic pulmonary disease. In a nationwide observational study in Denmark, social distancing, which was introduced to curb the spread of COVID-19, substantially reduced the risk of severe exacerbations, intensive care admissions, and all-cause mortality in COPD patients [1]. Social distancing was also shown to decrease hospital admissions for exacerbations due to common respiratory virus infections in this patient population [2]. Despite these beneficial effects of social distancing, the downside was that many patients experienced an increased sense of loneliness due to the imposed measures [3]. If this was the case for COPD patients, what would the effect of the pandemic and its measures be in patients with bronchiectasis?
Vestergård et al. conducted a study in 306 Danish patients using the Bronchiectasis Health Questionnaire, which consists of 10 questions. The median age of the participants was 68 years and 68% of participants were women. The period covered by the study was divided into 5 segments: December 2020-February 2021, March-May 2021, June-August 2021, September-November 2021, December 2021-February 2022, and March-May 2022.
The mean number of exacerbations declined from December 2020 to February 2021 to rise again in the period between September and November 2021, increasing until May 2022. Differences in the number of antibiotic courses used for the past 12 months – with December 2020–February 2021 being the reference group – showed a higher number of antibiotic courses used in September-November 2021 and December 2021-February 2022 (2.502 and 4.695, respectively). Regarding the daily symptoms (coughing bouts and sputum production), no significant differences have been observed across the various periods. Furthermore, in this study population, no correlation was found between social distancing and the sense of anxiousness [4].
- Saeed MI, et al. Epidemiol. 2022;191(5):874–885.
- Tan JY, et al. Thorax. 2021;76(5):512–513.
- Kusk KH, et al. COPD. 2021;18(5):549–556.
- Vestergård C. Exacerbations in bronchiectasis during and after COVID-19 lock-down. Nordic Lung Congress 2022, 01–03 June, Copenhagen, Denmark.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Exercise-induced laryngeal obstruction (EILO) is often misdiagnosed Next Article
Targeting treatable traits allows a personalised approach to management of (severe) asthma »
« Exercise-induced laryngeal obstruction (EILO) is often misdiagnosed Next Article
Targeting treatable traits allows a personalised approach to management of (severe) asthma »
Table of Contents: NLC 2022
Featured articles
Respiratory Disease and Physical Activity
Physical activity improves asthma control
Exercise training for IPF patients is feasible but access needs to be improved
Respiratory Disease and Reproduction
PRO-ART study: unravelling the link between asthma and subfertility
Early-onset and uncontrolled asthma: strong association with recurrent pregnancy loss
Palliative Care in Respiratory Diseases
Advance care planning
Biologics in Asthma
Treatable Traits in Obstructive Airway Diseases
Targeting treatable traits allows a personalised approach to management of (severe) asthma
Bronchiectasis
Challenges in Upper Airway Diseases
Exercise-induced laryngeal obstruction (EILO) is often misdiagnosed
The ULANC Group: working together in CRSwNP/asthma
Interstitial Lung Diseases (ILD)
Rheumatoid arthritis-associated ILD
Thoracic ultrasound: a new diagnostic imaging tool in RA-ILD?
Update on treatment of fibrotic ILD
Respiratory Failure
Lung Cancer Screening in the Nordics
Points of interest for radiologists screening for lung cancer
E-cigarettes
E-cigarettes impose detrimental effects on health
Effects of passive vaping in COPD patients
Vaping amongst adolescents: an alarming trend
Tuberculosis and Sarcoidosis
Detection of latent TB infection key to preventing the spread of the disease
Related Articles
August 17, 2022
Fatigue syndrome in sarcoidosis
August 17, 2022
New antigens in sarcoidosis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com